The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Open accessAbstract
Purpose: Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a logical approach for trials in recurrent GBM. Patients and Methods: In a randomized, controlled, phase II trial, 110 patients with progressive GBM after prior radiotherapy were randomly assigned to either erlotinib or a control arm that received treatment with either temozolomide or carmustine (BCNU). The primary end point was 6-month progression-free survival (PFS). Tumor specimens obtained at first surgery were investigated for EGFR expression; EGFRvIII mutants; EGFR amplification; EGFR mutations in exons 18, 19, and 21; and pAkt. These results were correlated with outcome. Pharmacokinetic analysis was part of the study. Results: Treatment was well tolerated in general; skin toxicity was the most frequent adverse effect of erlotinib. The 6-month PFS rate in the erlotinib arm was 11.4% (95% CI, 4.6% to 21.5%), and it was 24% in the control arm. Of all explored biomarkers, only low pAkt expression appeared to be of borderline significance to an improved outcome. None of the eight patients who had tumors with EGFRvIII mutant presence and PTEN expression had 6-month PFS. The use of enzyme-inducing anticonvulsants significantly increased erlotinib clearance, but pharmacokinetic findings were not related to outcome. Conclusion: Erlotinib has insufficient single-agent activity in unselected GBM. No clear biomarker associated with improved outcome to erlotinib was identified.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Self-citationLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Response criteria for phase II studies of supratentorial malignant glioma.
Macdonald, D. R., Cascino, T. L., Schold, S. C., & Cairncross, J. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1277 · Cited by 2,409
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
Stommel, J. M., Kimmelman, A. C., Ying, H., Nabioullin, R., Ponugoti, A. H., Wiedemeyer, R., Stegh, A. H., Bradner, J. E., Ligon, K. L., Brennan, C., et al. (2007) · Science · doi:10.1126/science.1142946 · Cited by 938
Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.
Frederick, L. A., Wang, X. Y., Eley, G. D., & James, C. D. (2000) · PubMed · Cited by 740
Phase II Trial of Gefitinib in Recurrent Glioblastoma
Rich, J. N., Reardon, D. A., Peery, T., Dowell, J. M., Quinn, J. A., Penne, K. L., Wikstrand, C. J., Van Duyn, L. B., Dancey, J. E., McLendon, R. E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.110 · Cited by 734
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
Haas-Kogan, D. A., Prados, M. D., Tihan, T., Eberhard, D. A., Jelluma, N., Arvold, N. D., Baumber, R., Lamborn, K. R., Kapadia, A., Malec, M., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji161 · Cited by 465
(2003) · PubMed · Cited by 269
Lassman, A. B., Rossi, M. R., Razier, J. R., Abrey, L. E., Lieberman, F. S., Grefe, C. N., Lamborn, K., Pao, W., Shih, A. H., Kuhn, J. G., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0421 · Cited by 252
Prados, M. D., Lamborn, K. R., Chang, S., Burton, E., Butowski, N., Malec, M., Kapadia, A., Rabbitt, J., Page, M. S., Fedoroff, A., et al. (2006) · Neuro-Oncology · doi:10.1215/s1522851705000451 · Cited by 218
Pelloski, C. E., Lin, E., Zhang, L., Yung, W. K. A., Colman, H., Liu, J.-L., Woo, S. Y., Heimberger, A. B., Suki, D., Prados, M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2202 · Cited by 179
How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial
Brandes, A. A., Tosoni, A., Amistà, P., Nicolardi, L., Grosso, D., Berti, F., & Ermani, M. (2004) · Neurology · doi:10.1212/01.wnl.0000140495.33615.ca · Cited by 134
Self-citationKouwenhoven, M. C. M., Kros, J. M., French, P. J., Stege, E. M. B., Graveland, W. J., TAPHOORN, M. J. B., Brandes, A. A., & van den Bent, M. J. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.05.021 · Cited by 115
Self-citationPerez-Soler, R. (2006) · Clinical Lung Cancer · doi:10.3816/clc.2006.s.008 · Cited by 110
Ling, J., Fettner, S. H., Lum, B. L., Riek, M., & Rakhit, A. K. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f2d8e4 · Cited by 96
EGFR tyrosine kinase domain mutations in human gliomas
Marie, Y., Carpentier, A. F., Omuro, A. M. P., Sanson, M., Thillet, J., Hoang‐Xuan, K., & Delattre, J. (2005) · Neurology · doi:10.1212/01.wnl.0000158654.07080.b0 · Cited by 79
Self-citationFrederick, L. A., Eley, G. D., Wang, X.-Y., & James, C. D. (2000) · Neuro-Oncology · doi:10.1093/neuonc/2.3.159 · Cited by 76
Vogelbaum, M. A., Peereboom, D. M., Stevens, G. H. J., Barnett, G. H., & Brewer, C. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.1558 · Cited by 72
Raizer, J. J., Lassman, A. B., & Rossi, M. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1-cor · Cited by 50
Cited by
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668
Self-citationExciting New Advances in Neuro-Oncology: The Avenue to a Cure for Malignant Glioma
Van Meir, E. G., Hadjipanayis, C. G., Norden, A. D., Shu, H. K., Wen, P. Y., & Olson, J. J. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20069 · Cited by 1,372
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Wen, P. Y., Weller, M., Lee, E. Q., Alexander, B. M., Barnholtz-Sloan, J. S., Barthel, F. P., Batchelor, T. T., Bindra, R. S., Chang, S. M., Chiocca, E. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa106 · Cited by 1,168
Self-citationMechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Metadata
- Authors
- van den Bent, M. J., Brandes, A. A., Rampling, R., Kouwenhoven, M. C. M., Kros, J. M., Carpentier, A. F., Clement, P. M., Frenay, M., Campone, M., Baurain, J.-F., Armand, J.-P., Taphoorn, M. J. B., Tosoni, A., Kletzl, H., Klughammer, B., Lacombe, D., & Gorlia, T.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-03-10
- Volume
- 27
- Issue
- 8
- Pages
- 1268-1274
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2086216067
- Cited by
- 575
- References
- 24
- FWCI
- 26.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.